Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of...
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.